• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Product
    • ibrexafungerp
    • Patent
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Refractory Invasive Fungal Infections
    • Invasive Candidiasis
    • Invasive Aspergillosis
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data

SCYNEXIS, Inc.

You are now leaving the SCYNEXIS Corporate Website.

I understand Cancel

Posters and Presentations

Science

Science

  • SCYNEXIS Research Platform
  • Publications and Presentations
  • Expanded Access
  • Publications and Presentations

  • Posters and Presentations
Clear Search
Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases<br><sup>Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)</sup>

Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases
Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)

Oliver A. Cornely MD, FECMM, FIDSA, FAAM, FACP
Consultant, Infectious Diseases
Director, European Mycology Excellence Center
University Hospital of Cologne
ECCMID 2019
April 2019

Successful Treatment of Two Patients with <em>Candida auris</em> Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study

Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study

D Juneja, O Singh, B Tarai, DA Angulo
ECCMID 2019
April 2019
Favourable Clinical Outcome of Two Patients with <em>Candida</em> spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study

Favourable Clinical Outcome of Two Patients with Candida spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study

Philipp Koehler, Oliver A. Cornerly, David Angulo
ECCMID 2019
April 2019
Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole Refractory Esophageal Candidiasis. A Case Report from the Furi Study

Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole Refractory Esophageal Candidiasis. A Case Report from the Furi Study

J Vazquez, Aprile Osborn, D Angulo
ECCMID 2019
April 2019
Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Annie Lee, Brendan Prideaux, Min Hee Lee, Matthew Zimmerman, Padmaja Paderu, Stephen A. Barat, David Angulo, David S. Perlin, Yanan Zhao
ECCMID 2019
April 2019
Efficacy of Ibrexafungerp (formerly SCY-078) Against <em>Pneumocystis</em> Pneumonia in a Murine Therapeutic Model.

Efficacy of Ibrexafungerp (formerly SCY-078) Against Pneumocystis Pneumonia in a Murine Therapeutic Model.

Stephen A. Barat, Katyna Borroto-Esoda, David A. Angulo, Alan Ashbaugh, Melanie Cushion
ECCMID 2019
April 2019
Ibrexafungerp: Activity against <em>Pneumocystis</em>

Ibrexafungerp: Activity against Pneumocystis

S. Barat
Superbugs and Superdrugs 2019
March 2019
Ibrexafungerp (formerly SCY-078) Displays Potent <em>In Vitro</em> Activity Against <em>C. glabrata</em> Isolates with Mutations in <em>fks</em> Genes

Ibrexafungerp (formerly SCY-078) Displays Potent In Vitro Activity Against C. glabrata Isolates with Mutations in fks Genes

Stephen Barat, Katyna Borroto-Esoda, David Angulo
ESCMID ASM 2018
September 2018

SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against <em>Candida</em>, <em>Aspergillus</em> and <em>Pneumocystis</em> spp.

SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against Candida, Aspergillus and Pneumocystis spp.

Stephen Barat, Katyna Borroto-Esoda, David Angulo
ISHAM 2018
June 2018

<em>In vitro</em> Activity of SCY-078 in Combination with Isavuconazole or Amphotericin B against Medically Important Moulds

In vitro Activity of SCY-078 in Combination with Isavuconazole or Amphotericin B against Medically Important Moulds

V. Petraitis, P. Kavaliauskas, R. Planciuniene, M.Viragailis, R.Petraitiene, S.Barat, K. Borroto-Esoada, D. Angulo, T. Walsh
ASM Microbe 2018
June 2018
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »

1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
View Google Map

© 2022 SCYNEXIS, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Contact Us